Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
41

Recommended

Headwinds in listed energy stocks likely to have passed

Esther Holloway | 30 March 2026

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.

Franco Granda | 30 March 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Tyger Fitzpatrick | 30 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,683.90	11.50	0.13%
CAC 40	7,834.90	62.45	0.80%
DAX 40	22,790.31	227.43	1.01%
Dow JONES (US)	45,216.14	49.50	0.11%
FTSE 100	10,228.56	100.60	0.99%
HKSE	24,788.14	37.35	0.15%
NASDAQ	20,794.64	153.72	-0.73%
Nikkei 225	51,063.72	822.13	-1.58%
NZX 50 Index	12,912.11	163.19	1.28%
S&P 500	6,343.72	0.00	0.00%
S&P/ASX 200	8,481.80	4.60	0.05%
SSE Composite Index	3,891.86	31.43	-0.80%